drugset / Trial / NCT00707772
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Phase 4
Completed
400 enrolled
Baqiyatallah Medical Sciences University
Baqiyatallah Research Center for Gastroenterology and Liver Diseases · collabGuilan University of Medical Sciences · collabIran University of Medical Sciences · collabShahid Beheshti University of Medical Sciences · collabTabriz Research Center for Gastroenterology and Liver Diseases · collabTehran Hepatitis Center · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection. We are trying the PEGASYS plus Ribavirin in Hemophilic patients with HCV.
Timeline
- Start
- 2007-03
- Primary completion
- 2009-09
- Completion
- 2009-09
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Peginterferon Alfa-2a (40KD) | Unknown | 180 ug | Other |
| Comparator | Ribavirin | Small molecule | 800 mg | Oral |
| Comparator | Ribavirin | Small molecule | 1000 mg | Oral |
| Comparator | Ribavirin | Small molecule | 1200 mg | Oral |